[b]Pancreatic Cancer (PC)[/b] is a disease predominately of the elderly with ~75% of PC cases being diagnosed in patient’s over 75 years old. PC proliferates rapidly, is asymptomatic at its earliest stages and when symptoms do present themselves they are non-specific. There are currently no early detection methods in use for PC. Currently the best option for patient survival is resection which can triple five year survival rate to 15% compared to the unrespectable stages of PC. Regrettably ~83% of patients present with advanced unrespectable disease and patient prognosis is extremely poor. The majority of patients ultimately develop resistant disease, for which treatment options have historically been limited, with treatment involving fluorouracil as a monotherapy or used in a combination therapy being standard. The recent approval of Onivyde for gemcitabine refractory disease in 2015 has improved survival of resistant patients, but there is a clear clinical need to diversify the treatment options for this patient cohort.

The current late-stage drugs in development for PC address this clinical need; however, results so far have been limited in their efficacy, with none demonstrating clinically transformative efficacy or safety. As a result, the growth in PC prevalence as a result of a global aging population, increasing diabetes and obesity prevalence is expected to be the key driver of this market throughout the forecast period.

[b]Check Complete Report @[/b] http://www.marketintelreports.com/report/gbihc377mr/pancreatic-cancer-therapeutics-in-major-developed-markets-to-2021--strong-late-stage-pipeline-holds-promise-for-increasingly-diverse-market-landscape

[b]Scope of the Report:[/b]
Global revenues for the PC market are forecast to rise at a moderate CAGR of 7.6% from $1.746bn in 2014 to $2.92bn in 2021.
•What factors are driving the market growth?
•How can the factors limiting growth are overcome in the future?
•The variation in mechanism of action has shifted away from the traditional chemotherapies, which dominate the marketed products, but account for only 7% of the pipeline. 44% of the pipeline is drugs inhibiting signal transduction.
•What are the dynamics of the remaining 49% of the pipeline?
•How does this reflect the need for novel targeted therapies?
•Key mechanisms of action across the pipeline include cancer immunotherapies against IAP repeat containing proteins, whole cell vaccines and targeted therapies against the PI3K/Akt/mTOR pathway.
•What is the scientific rationale behind these targets?
•Several drugs are expected to be approved during the forecast period: TH-302, ruxolitinib phosphate, Hyper Acute Pancreas, G17DT and clivatuzumab tetraxetan. However, their sales will be limited by their expected high costs.
•Where will these novel therapies fit into the current treatment algorithm for PC?
•The pipeline therapies, G17DT are expected to have the strongest performance, with revenues of $141m by 2021.
•How will the other late stage pipeline drugs perform commercially?

[b]Get Sample Brochure of the Report @[/b] http://www.marketintelreports.com/pdfdownload.php?id=gbihc377mr

[b]Reasons to Buy:[/b]
This report will allow you to -
•Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis.
•Visualize the composition of the pancreatic cancer market in terms of dominant molecule types and targets, highlighting the current unmet needs and how they can be addressed to allow a competitive understanding of gaps in the current market.
•Analyze the pancreatic cancer pipeline and stratify by stage of development, molecule type, and molecular target.
•Visualize the clinical safety and efficacy of late-stage pipeline drugs via a detailed heat map, outlining the results across major clinical trial endpoints.
•Understand the growth in patient epidemiology, annual therapy costs, and market revenues for the pancreatic cancer market globally and across the US, UK, France, Germany, Italy, Spain, Japan, and Canada.
•Identify commercial opportunities in the pancreatic cancer deals landscape by analyzing trends in licensing and co-development deals.

[b]Order a copy of Pancreatic Cancer Therapeutics Market @[/b] http://www.marketintelreports.com/purchase.php?id=gbihc377mr

[b]About us:[/b]
[b]MarketIntelReports (MIR)[/b] aim to empower our clients to successfully manage and outperform in their business decisions, we do this by providing Premium Market Intelligence, Strategic Insights and Databases from a range of Global Publishers.
A group of industry veterans who are well experienced in reputed international consulting firms after identifying the sourcing needs of MNCs for market intelligence, have together started this business savior MarketIntelReports.
[b]MIR[/b] intends to be a one-stop shop with an intuitive design, exhaustive database, expert assistance, secure cart checkout and data privacy integrated. It curates the list of reports, publishers and studies to ensure that the database is constantly updated to dynamically meet the targeted, specific needs of our clients.
[b]MarketIntelReports[/b] currently has more than 10,000 plus titles and 35+ publishers on our platform and growing consistently to fill the “Global Intelligence Demand – Supply Gap”. We cover more than 15 industry verticals being: Automotive, Electronics, Manufacturing, Pharmaceuticals, Healthcare, Chemicals, Building & Construction, Agriculture, Food & Beverages, Banking & Finance, Media and Government, Public Sector Studies.

[b]Contact us:[/b]
[b]Mayur S[/b]
Sales Manager
2711 Centerville Road, Suite 400,
Wilmington,
Delaware,
19808
United States
www.marketintelreports.com
[email protected]
Telephone: 1-302-684-6088